Pages that link to "Q38557486"

The following pages link to Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. (Q38557486):

Displaying 9 items.

• Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer (Q47561992) (← links)
• Cancer preventive effect of recombinant TRAIL by ablation of oncogenic inflammation in colitis-associated cancer rather than anticancer effect (Q49567330) (← links)
• IgG-single-chain TRAIL fusion proteins for tumour therapy. (Q54998541) (← links)
• Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480. (Q55396225) (← links)
• The miR-372-ZBTB7A Oncogenic Axis Suppresses TRAIL-R2 Associated Drug Sensitivity in Oral Carcinoma (Q89823504) (← links)
• Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy (Q90241548) (← links)
• Trimer form of tumor necrosis factor-related apoptosis inducing ligand induces apoptosis in canine cell lines derived from mammary tumors (Q90616999) (← links)
• Transcriptional Profiling of Human Peripheral Blood Mononuclear Cells Identifies Diagnostic Biomarkers That Distinguish Active and Latent Tuberculosis (Q92538932) (← links)
• A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors (Q92605076) (← links)